BeyondSpring Inc

BYSINASDAQ · USD
0.60USD0.00 (+0.04%)
112

BeyondSpring Inc (BYSI) Covered Calls

Read more

Running BYSI covered calls helps you generate income from BeyondSpring Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best BYSI covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If BYSI stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling BYSI covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given BYSI covered call is worth writing.

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers.

No illustrative rows to display.

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank89.29% High
  • Market cap (M$)25
  • 52 weeks high-75.41%
  • 52 weeks low42.86%
  • Analyst recommendationBuy
    2.00
  • Target price$1.25
    108.33% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-12-17
  • P/E—
  • Future P/E—
  • EPS (ttm)-0.16
  • EPS growth next 5 years—

As of Nov 13, 2026